{"entity":{"id":"nct05379946","kind":"trial","name":"Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Garsorasib and IN10018 in advanced solid tumours, run by InventisBio Co., Ltd, active and no longer recruiting.","summary":"Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors is a phase 1/2 interventional study registered as NCT05379946 by InventisBio Co., Ltd, with 92 participants enrolled, started 2022-10-12 and due to reach its primary completion in 2027-12-31. Interventions recorded: D-1553 and IN10018.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05379946","url":"https://clinicaltrials.gov/study/NCT05379946"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["garsorasib","in10018"],"companies":["inventisbio"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05379946","phase":"1/2","setting":"A Phase 1/2, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 in Combination With IN10018 in Subjects With Advanced or Metastatic Solid Tumors With KRasG12C Mutation","sponsor":"InventisBio Co., Ltd","enrolled":92,"outcomes":[]},"route":"/trials/nct05379946/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"garsorasib","kind":"drug","name":"Garsorasib","route":"/drugs/garsorasib/"},{"id":"in10018","kind":"drug","name":"IN10018","route":"/drugs/in10018/"}],"company":[{"id":"inventisbio","kind":"company","name":"InventisBio","route":"/companies/inventisbio/"}]}}